| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Harrow, Inc.'s insiders have reduced their positions by a net 11,250 shares worth roughly $450K.
HROW sits in the Pharmaceuticals industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.68M | $146.05M | - | |
| CEO | 3.00M | $90.48M | - | |
| CFO | 814.7K | $24.36M | - | |
| Dir | 1.0K | $31.1K | - | |
| Dir | 1.0K | $31.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2018 | Kammer Robert J | - | Sell | 10,000 | $4.21 | $42,100.00 | -1.1% | |
| Oct 15, 2018 | Kammer Robert J | Director | Sell | 10,000 | $3.00 | $30,000.00 | -1.1% | |
| Sep 4, 2018 | Kammer Robert J | - | Sell | 10,000 | $3.00 | $30,000.00 | -1.1% | |
| Aug 10, 2018 | Kammer Robert J | Director | Sell | 130,000 | $3.00 | $390,000.00 | -12.3% | |
| Jul 17, 2017 | Kammer Robert J | Director | Sell | 10,000 | $3.05 | $30,526.00 | -0.9% | |
| Dec 19, 2016 | Boll Andrew R. | Chief Financial Officer | Buy | 39,000 | $1.79 | $69,810.00 | +260.0% | |
| Dec 19, 2016 | Baum Mark L66 | Chief Executive Officer | Buy | 156,000 | $1.79 | $279,240.00 | +91.9% | |
| Dec 19, 2016 | Lindstrom Richard L Md65 | Director | Buy | 100,000 | $1.79 | $179,000.00 | New | |
| Mar 11, 2016 | Opaleye Management Inc.60 | 10% Owner | Buy | 45,000 | $3.65 | $164,250.00 | +3.7% | |
| Jun 30, 2015 | Opaleye Management Inc.60 | 10% Owner | Buy | 35,000 | $7.90 | $276,500.00 | +3.0% |